Clinical trials: Pancreas Cancer, Metastatic
- Condition Pancreas Cancer, Metastatic
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Pancreatic Cancer
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer.
- Trial name
- NCT01214720
- Testing
- bevacizumab [Avastin]
- Where
- 101 sites in Australia, Austria and 19 more
- Volunteers
- 607 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Ductal Adenocarcinoma
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT02981342
- Testing
- Abemaciclib, LY3023414, Gemcitabine
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to determine whether S-1 is effective in slowing tumor activity in participants with locally advanced or metastatic pancreatic cancer who have not had chemotherapy.
- Trial name
- NCT00651742
- Testing
- S-1
- Volunteers
- 28 people
- Sponsor
- Taiho Oncology, Inc.
Pancreatic Adenocarcinoma
A Study of MLN0264 in Patients With Pancreatic Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.
- Trial name
- NCT02202785
- Testing
- MLN0264
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum…
- Trial name
- POLO (NCT02184195)
- Testing
- Olaparib
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
- Trial name
- NCT01124786
- Testing
- CO-1.01, Gemcitabine
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Clovis Oncology, Inc.
Metastatic Pancreatic Cancer
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
To evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteria
- Trial name
- NCT02570711
- Testing
- ACP-196, Nab-paclitaxel, Gemcitabine
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Acerta Pharma BV
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic…
- Trial name
- MAESTRO (NCT01746979)
- Testing
- TH-302, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 693 people
- Sponsor
- ImmunoGenesis
Pancreatic Adenocarcinoma
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
The research trial is testing the experimental treatment MSC1936369B in combination with Gemcitabine, in subjects with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT01016483
- Testing
- Pimasertib, Gemcitabine
- Where
- 2 sites in United States, Germany
- Volunteers
- 141 people
- Sponsor
- EMD Serono
Pancreatic Cancer
An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed.
- Trial name
- NCT01782690
- Testing
- erlotinib, gemcitabine
- Where
- Germany
- Volunteers
- 338 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer.
- Trial name
- NCT00652366
- Testing
- Erlotinib, escalating dose, Erlotinib, standard dose, Gemcitabine
- Where
- 89 sites in Argentina, Australia and 21 more
- Volunteers
- 467 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreatic Cancer
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Phase III Metastatic Pancreatic Cancer
- Trial name
- NCT00844649
- Testing
- Albumin-bound paclitaxel (ABI-007), Gemcitabine
- Where
- 193 sites in United States, Australia and 9 more
- Volunteers
- 861 people
- Sponsor
- Celgene
Carcinoma, Metastatic Pancreatic Adenocarcinoma
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
- Trial name
- NCT03611556
- Testing
- Oleclumab, Durvalumab, Gemcitabine
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 213 people
- Sponsor
- MedImmune LLC
Metastatic Pancreatic Ductal Adenocarcinoma
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD…
- Trial name
- NCT02501902
- Testing
- Palbociclib, Nab-Paclitaxel
- Where
- 26 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Pfizer
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated mPDAC.
- Trial name
- daNIS-1 (NCT04390763)
- Testing
- NIS793, Spartalizumab, gemcitabine
- Where
- 31 sites in United States, Australia and 12 more
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Neuroendocrine Tumors
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreatic neuroendocrine tumors.
- Trial name
- NCT02842749
- Testing
- everolimus
- Where
- 5 sites in China
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals